Physician profile
Brian David Jaffe
NPI 1063407799
$5,768.42
in general payments reported to CMS, 2019-2025
18 companies · $51.75 in 2025
The $51.75 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,136 · 2020: $230 · 2021: $1,583 · 2022: $158 · 2023: $1,192 · 2024: $418 · 2025: $51.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,646 · Travel and Lodging: $16.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,645.81 |
| Travel and Lodging | $16.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $2,102.67 | 2019 | |
| Medtronic, INC. | $1,454.79 | 2021-2024 | Micra, Cobalt Dr Mri Surescan |
| Abbott Laboratories | $1,266.55 | 2020-2021 | |
| Biosense Webster, INC. | $344.90 | 2021-2025 | Nuvision Ice Catheter, Na, Carto 3 |
| Medtronic Vascular, INC. | $102.67 | 2020 | |
| Boston Scientific Corporation | $101.50 | 2023-2024 | Watchman Flx, Watchman |
| Astrazeneca Pharmaceuticals LP | $90.68 | 2019-2023 | Evusheld |
| Cardiofocus, INC. | $85.80 | 2021 | |
| Janssen Pharmaceuticals, INC | $59.69 | 2021-2024 | Xarelto |
| Atricure, INC. | $55.74 | 2020 | |
| Cordis US Corp. | $22.24 | 2025 | Mynx Control Venous |
| Cardiva Medical, INC. | $16.12 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.34 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $13.55 | 2024 | Opsumit |
| Preventice Services, LLC | $13.30 | 2021 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $11.98 | 2021 | |
| Pfizer INC. | $11.90 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Jaffe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.